Sante Capital Fund’s AbbVie ABBV Stock Holding History

Sante Capital Fund’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.36M	Buy	+10,153	New	+$1.46M	2.79%	6

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sante Capital Fund's ABBV Position: Q3 2022 in Review

Sante Capital Fund opened a new position in AbbVie (ABBV) in Q3 2022: 10,153 shares worth $1.36M. The stake represents 2.79% of the portfolio and ranks #6 among its holdings.

2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Sante Capital Fund held 10,153 shares of AbbVie worth $1.36M as of Q3 2022.
AbbVie was a new Sante Capital Fund position in Q3 2022.
AbbVie made up 2.79% of Sante Capital Fund's portfolio in Q3 2022, its #6 holding.
2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Sante Capital Fund's 13F filing for Q3 2022, filed 14 Nov 2022.